Adjuvant Chemotherapy or Radiotherapy in Resectable Gastric Cancer
Author Information
Author(s): W.H. Allum, M.T. Hallissey, L.C. Ward, M.S. Hockey
Primary Institution: British Stomach Cancer Group
Hypothesis
Does adjuvant chemotherapy or radiotherapy provide a survival advantage in operable gastric cancer?
Conclusion
Neither form of adjuvant therapy provides any survival advantage, and surgery remains the principal treatment for operable gastric cancer.
Supporting Evidence
- 334 patients died during the study, with 292 deaths attributed to recurrent cancer.
- The median survival for all patients was 15 months.
- Adjuvant therapies did not show a significant effect on survival rates.
- Only 62% of patients completed the planned chemotherapy cycles.
Takeaway
The study looked at whether adding chemotherapy or radiotherapy after surgery helps people with stomach cancer live longer, but it found that it doesn't.
Methodology
A prospective, randomised controlled trial comparing surgery alone with surgery plus adjuvant radiotherapy or chemotherapy in operable gastric cancer.
Potential Biases
Potential biases due to protocol violations and variations in treatment adherence.
Limitations
The study did not find a survival advantage for adjuvant therapies, and many patients did not complete the treatment as planned.
Participant Demographics
Patients aged 15 to 74 years who underwent surgical resection for adenocarcinoma of the stomach.
Statistical Information
P-Value
0.07
Statistical Significance
p=0.07
Want to read the original?
Access the complete publication on the publisher's website